Alexander Weis - OncoVista Innovative Chairman

Dr. Alexander L. Weis, Ph.D., is Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Secretary of OncoVista Innovative Therapies, Inc. Dr. Weis is the principal founder of OncoVistaSub and was its Chairman, Chief Executive Officer, and President since its inception in September 2004. Since February 2009, Dr. Weis also serves as AdnaGens Chief Executive Officer. Dr. Weis is a recognized leader and pioneer in the biotechnology and pharmaceutical industries and has led pharmaceutical companies through all stages from startup through public offerings and as a manager of a substantial public company. Prior to forming our company, from 1989 to September 2004, Dr. Weis served as President of Lipitek International, Inc., a specialty pharmaceutical company that Dr. Weis founded. Dr. Weis was a cofounder of ILEX Oncology, which became a publicly traded company in 1997 and was later acquired by Genzyme Corporation in a stock transaction valued at over 1 billion. Dr. Weis served as ILEXS Chief Scientific Officer and Executive Vice President from its founding in 1994 through 1998. Dr. Weis has worked for Vector Therapeutics, MykoBiologics, the Cancer Therapy and Research Center, Sterling Drugs, the Eastman Kodak Company and the Weizmann Institute of Science. Dr. Weis received his Ph.D. in Organic Chemistry from the Novosibirsk Institute of Organic Chemistry. Dr. Weis is a scientist and inventor, with over 60 publications and 30 patents. He is a Chartered Chemist and Fellow of the Royal Society of Chemistry, and was selected as the South Texas Entrepreneur of the Year in 1996. since 2009.